Treatment of intravascular lymphoma – pro
Inravascular lymphoma is a fairly new entity that is only recently described. It is is a rare form of diffuse LBCL characterized by preferential intravascular growth of malignant lymphocytes, aggressive behavior, and an often fatal course. IVLBCL usually affects elderly patients with poor performance status, elevated lactic dehydrogenase serum levels, anemia, and B symptoms. There is no standard therapy and most information about therapy comes from case reports. CHOP, adriamycin and other regimens have been tried. There is a report of excessive toxicity from rituxan. There is no credible medical evidence supporting an autologous transplant after a compete response.
Maurilio Ponzoni, Andrés J.M. Ferreri, Elías Campo, Fabio Facchetti, Luca Mazzucchelli, Tadashi Yoshino, Takuhei Murase, Stefano A. Pileri, Claudio Doglioni, Emanuele Zucca, Franco Cavalli, Shigeo Nakamura Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting Journal of Clinical Oncology, Vol 25, No 21 (July 20), 2007: pp. 3168-3173
Joachim M. Baehring, Janina Longtine and Fred H. Hochberg
A New Approach to the Diagnosis and Treatment of Intravascular Lymphoma Journal of Neuro-Oncology Volume 61, Number 3, 237-248,
WU Shang-Ju; CHOU Wen-Chien ; KO Bo-Sheng ; TEN Hwei-Fang ; Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma Haematologica 2007, vol. 92, no1, pp. 141-142